Floatz logo

MODERNA COVID-19 VACCINE RNA

Multiple Myeloma

Barbara Ann Karmanos Cancer InstitutevaccinePhase 2Active
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
59/ 100

Competitive context

497 Active assets in the Multiple Myeloma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

MODERNA COVID-19 VACCINE RNA is also rated in:

secondary progressive multiple sclerosisDormant
B
Indicative ·
62 / 100
View asset →
AL amyloidosisDormant
CCC
Indicative ·
55 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →